Modality
Radioligand
MOA
PARPi
Target
PRMT5
Pathway
Incretin
NB
Development Pipeline
Preclinical
Sep 2019
→ Apr 2031
PreclinicalCurrent
NCT07599399
1,782 pts·NB
2019-09→2025-04·Completed
NCT06662204
2,278 pts·NB
2023-03→2031-04·Active
4,060 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2011mo agoInterim· NB
2031-04-105.0y awayInterim· NB
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Complet…
Preclinical
Active
Catalysts
Interim
2025-04-20 · 11mo ago
NB
Interim
2031-04-10 · 5.0y away
NB
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07599399 | Preclinical | NB | Completed | 1782 | NT-proBNP |
| NCT06662204 | Preclinical | NB | Active | 2278 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |